How it works
IGF-1 LR3 is a recombinant analog of insulin-like growth factor 1 carrying two modifications: glutamic acid at position 3 replaced by arginine, and a 13-residue extension on the N-terminus. Both target the same problem — native IGF-1 is largely bound by IGF binding proteins in circulation, which limits the free fraction available to the receptor. The modifications sharply reduce IGFBP affinity, so a greater proportion stays unbound. Downstream, receptor engagement runs through the PI3K/Akt and MAPK pathways studied in proliferation and differentiation models.
Learn more about the science →Certificate of Analysis+
LC-MS identity, HPLC purity, mass spec confirmation, endotoxin by LAL, appearance. Third-party ISO-17025 verified.
View full certificate →Specifications+
Storage & handling+
Lyophilized: −20°C, protected from light. Reconstituted: 2–8°C. A 9 kDa protein is shear-sensitive — swirl, never vortex, and avoid repeated freeze-thaw.
We ship in insulated parcels with phase-change cooling and a tamper-evident seal.
FAQs+
What does the LR3 designation mean?+
Long R3: the R3 is the arginine-for-glutamate substitution at position 3, and Long refers to the 13-residue N-terminal extension. Both reduce binding-protein affinity.
Why does binding-protein affinity matter?+
Native IGF-1 circulates largely bound to IGFBPs, which limits the fraction available to the receptor. The LR3 modifications are aimed squarely at that constraint.
Why is IGF-1 LR3 in Anabo?+
Anabo covers anabolic and recovery research. IGF-1 receptor signalling through PI3K/Akt sits in that scope.
Any handling specifics?+
It is a protein rather than a short peptide. Swirl instead of vortexing, keep freeze-thaw cycles to a minimum, and expect aggregation rather than hydrolysis as the failure mode.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Francis G.L. et al. Biochem J 233 (1986): 207–213.
- [02] Tomas F.M. et al. J Endocrinol 137 (1993): 413–421.
Verified buyer notes
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”